Secondary amyloidosis in ankylosing spondylitis

Basit Öğe Kaydı
dc.authoridInman, Robert/0000-0002-4750-1422
dc.contributor.authorDonmez, Salim
dc.contributor.authorPamuk, Omer Nuri
dc.contributor.authorPamuk, Gulsum Emel
dc.contributor.authorAydogdu, Erkan
dc.contributor.authorInman, Robert
dc.date.accessioned2024-06-12T10:51:52Z
dc.date.available2024-06-12T10:51:52Z
dc.date.issued2013
dc.departmentTrakya Üniversitesien_US
dc.description.abstractWe evaluated the frequency of secondary amyloidosis, associated clinical features, and outcomes in ankylosing spondylitis (AS) patients diagnosed in the last decade. The medical records of AS patients diagnosed at single academic medical center were reviewed for clinical evidence of amyloidosis. During routine follow-up, routine urinalysis was performed at each visit; patients with significant proteinuria underwent rectal biopsy. We diagnosed 8 clinically apparent amyloidosis patients (1.1 %) in our cohort of 730 AS patients (508 males, 222 females). Four patients undergoing hemodialysis were diagnosed secondary amyloidosis. Three patients had nephrotic syndrome and renal dysfunction and one patient had non-nephrotic proteinuria. When AS patients with amyloidosis were compared to AS controls, it was observed that the amyloidosis group was older, had longer disease duration, higher initial BASDAI scores, and ESR values, and more frequent peripheral arthritis (p < 0.05). Logistic regression analysis revealed that the initial BASDAI level was an independent predictor for the development of secondary amyloidosis (OR:2.36). Six patients were administered anti-TNF therapy. The clinical findings resolved in these. In 2 patients with nephrotic syndrome and renal dysfunction, in addition to clinical improvement, there was a decrement in proteinuria; renal function improved or remained stable. Anti-TNF therapy is safe and effective in patients with renal failure, and at an earlier stage, appears effective in improving renal function. The development of proteinuria in AS patients should occasion a search for underlying amyloidosis.en_US
dc.identifier.doi10.1007/s00296-012-2646-3
dc.identifier.endpage1729en_US
dc.identifier.issn0172-8172
dc.identifier.issue7en_US
dc.identifier.pmid23283540en_US
dc.identifier.scopus2-s2.0-84879690743en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1725en_US
dc.identifier.urihttps://doi.org/10.1007/s00296-012-2646-3
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18494
dc.identifier.volume33en_US
dc.identifier.wosWOS:000321259500010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofRheumatology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnkylosing Spondylitisen_US
dc.subjectSecondary Amyloidosisen_US
dc.subjectAnti-TNF Therapyen_US
dc.subjectTNF Alphaen_US
dc.subjectNecrosis-Factor-Alphaen_US
dc.subjectRheumatoid-Arthritisen_US
dc.subjectDiseasesen_US
dc.subjectEtanercepten_US
dc.subjectMortalityen_US
dc.subjectEfficacyen_US
dc.subjectReceptoren_US
dc.titleSecondary amyloidosis in ankylosing spondylitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu